Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuromyelitis Optica | 19 | 2024 | 266 | 3.010 |
Why?
|
| Neurology | 4 | 2022 | 785 | 1.690 |
Why?
|
| Autoantibodies | 9 | 2024 | 2114 | 1.090 |
Why?
|
| Aquaporin 4 | 6 | 2022 | 161 | 0.910 |
Why?
|
| Multiple Sclerosis | 8 | 2024 | 3229 | 0.870 |
Why?
|
| Remote Consultation | 3 | 2020 | 242 | 0.810 |
Why?
|
| Paresthesia | 1 | 2023 | 160 | 0.790 |
Why?
|
| Nervous System Diseases | 2 | 2022 | 1660 | 0.760 |
Why?
|
| Brain Death | 2 | 2021 | 360 | 0.700 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2021 | 45 | 0.700 |
Why?
|
| Optic Neuritis | 1 | 2022 | 173 | 0.680 |
Why?
|
| Cerebrum | 1 | 2021 | 132 | 0.660 |
Why?
|
| Telemedicine | 3 | 2022 | 3110 | 0.640 |
Why?
|
| Optic Atrophy, Hereditary, Leber | 1 | 2019 | 50 | 0.630 |
Why?
|
| Neurologic Examination | 1 | 2021 | 913 | 0.580 |
Why?
|
| Spinal Cord | 6 | 2021 | 1811 | 0.580 |
Why?
|
| Agraphia | 1 | 2015 | 8 | 0.510 |
Why?
|
| Handwriting | 1 | 2015 | 26 | 0.510 |
Why?
|
| Immunity | 1 | 2021 | 1002 | 0.470 |
Why?
|
| Vision Disorders | 1 | 2019 | 1090 | 0.390 |
Why?
|
| HLA-DR Antigens | 2 | 2010 | 609 | 0.380 |
Why?
|
| Immunoglobulin G | 7 | 2024 | 4560 | 0.350 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 2024 | 667 | 0.330 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2010 | 50 | 0.330 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2011 | 306 | 0.330 |
Why?
|
| Optic Nerve | 4 | 2021 | 568 | 0.300 |
Why?
|
| Referral and Consultation | 1 | 2021 | 3618 | 0.290 |
Why?
|
| Phenotype | 2 | 2024 | 16718 | 0.290 |
Why?
|
| Mycophenolic Acid | 4 | 2024 | 348 | 0.280 |
Why?
|
| Recovery of Function | 1 | 2015 | 2978 | 0.240 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2024 | 40 | 0.230 |
Why?
|
| Myasthenia Gravis | 2 | 2019 | 214 | 0.200 |
Why?
|
| Mutation, Missense | 1 | 2011 | 2592 | 0.190 |
Why?
|
| Clarithromycin | 1 | 2021 | 87 | 0.180 |
Why?
|
| Plasmapheresis | 1 | 2021 | 205 | 0.170 |
Why?
|
| Autoimmune Diseases | 2 | 2024 | 2255 | 0.170 |
Why?
|
| Arm | 1 | 2023 | 591 | 0.170 |
Why?
|
| Restless Legs Syndrome | 1 | 2023 | 235 | 0.170 |
Why?
|
| Immunologic Factors | 4 | 2022 | 1592 | 0.170 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 2020 | 92 | 0.170 |
Why?
|
| Color Vision Defects | 1 | 2019 | 28 | 0.160 |
Why?
|
| Scotoma | 1 | 2019 | 128 | 0.150 |
Why?
|
| Hallucinations | 1 | 2021 | 373 | 0.150 |
Why?
|
| Leg | 1 | 2023 | 1087 | 0.150 |
Why?
|
| Humans | 40 | 2024 | 767040 | 0.150 |
Why?
|
| Steroids | 1 | 2022 | 937 | 0.140 |
Why?
|
| Encephalitis | 1 | 2021 | 441 | 0.140 |
Why?
|
| Lyme Neuroborreliosis | 1 | 2017 | 50 | 0.140 |
Why?
|
| Orbit | 1 | 2019 | 459 | 0.130 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2018 | 253 | 0.130 |
Why?
|
| Paralysis | 1 | 2017 | 250 | 0.130 |
Why?
|
| Limbic Encephalitis | 1 | 2015 | 36 | 0.120 |
Why?
|
| Genetic Counseling | 1 | 2019 | 635 | 0.120 |
Why?
|
| Brain Stem | 2 | 2021 | 858 | 0.120 |
Why?
|
| Brain | 3 | 2020 | 27163 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2011 | 16036 | 0.110 |
Why?
|
| Recurrence | 3 | 2024 | 8504 | 0.110 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2020 | 1164 | 0.110 |
Why?
|
| Retrospective Studies | 9 | 2024 | 81659 | 0.110 |
Why?
|
| Neostriatum | 1 | 2014 | 231 | 0.100 |
Why?
|
| Middle Aged | 15 | 2024 | 223233 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2011 | 5716 | 0.100 |
Why?
|
| Female | 20 | 2024 | 396660 | 0.100 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 1883 | 0.100 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 951 | 0.100 |
Why?
|
| Acute Disease | 1 | 2022 | 7236 | 0.090 |
Why?
|
| Tissue Donors | 1 | 2021 | 2387 | 0.090 |
Why?
|
| Heart Arrest | 1 | 2021 | 1516 | 0.090 |
Why?
|
| Medicine | 1 | 2018 | 944 | 0.090 |
Why?
|
| Adult | 11 | 2024 | 223317 | 0.090 |
Why?
|
| Minnesota | 1 | 2011 | 339 | 0.090 |
Why?
|
| Fibrinolytic Agents | 1 | 2020 | 2079 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 12986 | 0.090 |
Why?
|
| Male | 15 | 2024 | 364203 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2024 | 36582 | 0.080 |
Why?
|
| Secondary Prevention | 3 | 2011 | 1472 | 0.080 |
Why?
|
| RNA Splice Sites | 1 | 2011 | 212 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2021 | 2191 | 0.080 |
Why?
|
| 5' Untranslated Regions | 1 | 2011 | 255 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 2783 | 0.080 |
Why?
|
| Visual Acuity | 1 | 2019 | 2714 | 0.080 |
Why?
|
| Disability Evaluation | 3 | 2011 | 1829 | 0.080 |
Why?
|
| 3' Untranslated Regions | 1 | 2011 | 515 | 0.080 |
Why?
|
| Organ Specificity | 1 | 2013 | 1966 | 0.080 |
Why?
|
| Child | 6 | 2024 | 80771 | 0.080 |
Why?
|
| Retina | 1 | 2019 | 2659 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2008 | 696 | 0.070 |
Why?
|
| Vomiting | 1 | 2010 | 655 | 0.070 |
Why?
|
| Young Adult | 4 | 2024 | 59980 | 0.070 |
Why?
|
| Gene Frequency | 2 | 2011 | 3621 | 0.070 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2007 | 425 | 0.070 |
Why?
|
| Health Expenditures | 1 | 2018 | 2390 | 0.060 |
Why?
|
| Transplantation, Autologous | 1 | 2011 | 2118 | 0.060 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 1996 | 0.060 |
Why?
|
| Astrocytes | 1 | 2013 | 1352 | 0.060 |
Why?
|
| Treatment Outcome | 7 | 2022 | 65295 | 0.060 |
Why?
|
| Exons | 1 | 2011 | 2391 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 2 | 2021 | 7469 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 3431 | 0.060 |
Why?
|
| Haplotypes | 1 | 2011 | 2722 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3804 | 0.060 |
Why?
|
| Disease Susceptibility | 1 | 2010 | 1791 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 39317 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2011 | 22254 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3112 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3234 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2011 | 4114 | 0.050 |
Why?
|
| Alleles | 2 | 2010 | 6893 | 0.050 |
Why?
|
| Immunosuppressive Agents | 2 | 2015 | 4210 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 20169 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 9245 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2009 | 1361 | 0.040 |
Why?
|
| Linear Models | 1 | 2011 | 5875 | 0.040 |
Why?
|
| Electronics | 1 | 2021 | 316 | 0.040 |
Why?
|
| Parkinson Disease | 1 | 2014 | 2886 | 0.040 |
Why?
|
| Disease Progression | 3 | 2024 | 13646 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2009 | 2270 | 0.040 |
Why?
|
| Complement Inactivating Agents | 1 | 2019 | 53 | 0.040 |
Why?
|
| Hospitals, General | 1 | 2024 | 804 | 0.040 |
Why?
|
| Adolescent | 4 | 2024 | 89046 | 0.040 |
Why?
|
| Prednisone | 1 | 2024 | 1566 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2011 | 9660 | 0.040 |
Why?
|
| Stroke | 1 | 2020 | 9746 | 0.040 |
Why?
|
| Aged | 7 | 2021 | 171319 | 0.040 |
Why?
|
| Antirheumatic Agents | 1 | 2007 | 1379 | 0.040 |
Why?
|
| Borrelia burgdorferi Group | 1 | 2017 | 95 | 0.040 |
Why?
|
| Rats | 1 | 2013 | 23713 | 0.030 |
Why?
|
| New England | 1 | 2020 | 1058 | 0.030 |
Why?
|
| Complement System Proteins | 1 | 2019 | 738 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 12536 | 0.030 |
Why?
|
| Genotype | 1 | 2010 | 13035 | 0.030 |
Why?
|
| Logistic Models | 1 | 2010 | 13284 | 0.030 |
Why?
|
| Workflow | 1 | 2020 | 859 | 0.030 |
Why?
|
| Office Visits | 1 | 2018 | 595 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 935 | 0.030 |
Why?
|
| Cost Savings | 1 | 2018 | 904 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 15925 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2020 | 1512 | 0.030 |
Why?
|
| Animals | 4 | 2015 | 168965 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 2028 | 0.020 |
Why?
|
| Dysphonia | 1 | 2014 | 144 | 0.020 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 59548 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2020 | 2505 | 0.020 |
Why?
|
| Area Postrema | 1 | 2010 | 6 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2017 | 1477 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2020 | 2054 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 3212 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 2702 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 24299 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 18063 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 1142 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 21178 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2009 | 717 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2020 | 54886 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2024 | 4745 | 0.020 |
Why?
|
| Receptors, Cholinergic | 1 | 2009 | 243 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2018 | 14766 | 0.020 |
Why?
|
| Neurons | 1 | 2007 | 9517 | 0.020 |
Why?
|
| Blood Donors | 1 | 2009 | 343 | 0.020 |
Why?
|
| Mice | 1 | 2013 | 81912 | 0.020 |
Why?
|
| Neuromuscular Junction | 1 | 2009 | 399 | 0.020 |
Why?
|
| Massachusetts | 1 | 2018 | 8890 | 0.020 |
Why?
|
| Brazil | 1 | 2009 | 1250 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 9410 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2020 | 6282 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2009 | 2342 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 6550 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2009 | 2276 | 0.010 |
Why?
|
| Risk Factors | 1 | 2011 | 74886 | 0.010 |
Why?
|
| Age Distribution | 1 | 2009 | 2870 | 0.010 |
Why?
|
| Age of Onset | 1 | 2009 | 3344 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2009 | 2741 | 0.010 |
Why?
|
| Physicians | 1 | 2018 | 4593 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 4855 | 0.010 |
Why?
|
| Medicare | 1 | 2018 | 6813 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8736 | 0.010 |
Why?
|
| Time Factors | 1 | 2020 | 40154 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2010 | 42606 | 0.010 |
Why?
|
| Comorbidity | 1 | 2009 | 10582 | 0.010 |
Why?
|
| United States | 1 | 2018 | 72971 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 18330 | 0.000 |
Why?
|
Concepts
(181)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(50)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_